Stockreport

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopath...

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – On track to deliver full 12-week Part D readout in 2Q 2026 and Phase 3 start in 4Q 2026 – BOULDER, Colo. Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., [Read more]